Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study.

ABSTRACT:

Background

Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and Türkiye.

Methods

Medical records (2010-2011) of patients (≥ 18 years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT).

Results

Of 1511 patients analyzed (median age: 59.5 years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common

SUBMITTER: Kim K 

PROVIDER: S-EPMC12304004 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature